2025 outlook The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance: Prior guidance May 1 update Change at midpoint Y/Y growth rate Total revenue $3.025 - $3.085 billion $3.070 - $3.120 billion $40.0 million 12% Screening $2.350 - $2.390 billion $2.390 - $2.425 billion $37.5 million 14% Precision Oncology $675 - $695 million $680 - $695 million $2.5 million 5% Adjusted EBITDA $410 - $440 million $425 - $455 million $15.0 million 36% First-quarter 2025 conference call & webcast Company management will host a conference call and webcast on Thursday, May 1, 2025, at 5 p.m. ET to discuss first-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents the following non-GAAP measures: Core revenue — Core revenue is calculated to adjust for recent acquisitions and divestitures and foreign currency exchange rate fluctuations. Revenue from recent acquisitions is adjusted for the 12 months following acquisition when the periods are not comparable. To exclude the impact of change in foreign currency exchange rates from the prior per

later in the release …

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.